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ABSTRACT 
Background: Rheumatoid arthritis (RA) is a chronic, inflammatory disease 
affecting synovial joints. Patients with persistent, active disease have tradi- 
tionally been treated with disease-modifying antirheumatic drugs (DMARDs) 
(eg, methotrexate) or biologic agents (eg, tumor necrosis factor [TNF] antago- 
nists). However, patients may discontinue these treatments due to toxicity, 
infection, or lack of efficacy. Two additional biologic therapies--rituximab and 
abatacept--are currently available for TNF-antagonist inadequate responders. 
Abatacept is also indicated for inadequate r sponders to traditional DMARDs. 
Objectives: The aims of this review was to provide an overview of the issues 
surrounding the treatment of RA patients experiencing inadequate responses 
to current reatment and to discuss the current and future impact of abatacept 
on the RA treatment armamentarium. 
Methods: The MEDLINE, EMBASE, and BIOSIS databases were searched 
(search dates: January 1, 2000-September 19, 2007) using the terms abatacept 
or CTLA-4 or Orencia with rheumatoid arthritis. Full text articles in English were 
selected for relevance, and only articles presenting primary clinical trial data 
from randomized, placebo-controlled, clinical trials of abatacept were included. 
This review focused on the Phase III trials of abatacept in methotrexate and/or 
TNF-antagonist inadequate r sponders, as these trials had the largest number 
of patients and the longest study durations. 
Results: The literature search initially yielded 848 papers. A total of 12 ar- 
ticles fulfilled the inclusion criteria. Abatacept is a novel agent hat has been 
reported to reduce the signs and symptoms of RA in patients with active RA 
with an inadequate response to DMARDs and/or TNF-antagonist treatment. 
In both of these patient populations, treatment with abatacept was found 
to provide clinically meaningful health-related quality-of-life benefits, such 
as improvements in physical function, activity limitation, sleep, and fatigue. 
Abatacept was reported to have a consistent safety and tolerability profile, with 
a low rate (3.5%-4.2%) of discontinuation due to adverse vents. 
Conclusion: The efficacy and tolerability data from Phase III clinical trials 
suggest hat abatacept is an effective and generally well tolerated treatment 
option for RA patients with an inadequate response to methotrexate and/or 
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INTRODUCTION 
Rheumatoid arthrit is (RA) is a chronic, inf lammatory disease occurr ing in -3 
of 10,000 adults worldwide and in -1% of the adult population in the United 
States. 1 Although RA affects a wide range of synovial joints, the most com- 
monly involved are those of the hands, knees, and feet. 2 
The American College of Rheumatology (ACR) guidelines for the treatment 
of RA recommend that all patients with a diagnosis of RA be treated with 
disease-modifying antirheumatic drugs (DMARDs) within 3 months of diagno- 
sis. 3 Traditional DMARDs, such as methotrexate, are frequently used as first-line 
treatment for in the management of moderate-to-severe RA. 4 The primary reason 
reported for discontinuation of traditional DMARD treatment has been adverse 
events (AEs), 5-9 with studies reporting that 43% to 53% of patients permanently 
discontinued treatment due to tolerability issues. 5,1° Patients may also experi- 
ence a lack of efficacy with traditional DMARD treatment. 5,1° This was found in a 
retrospective study of 760 patient medical records, in which up to 47% of patients 
discontinued DMARD treatment due to an inadequate response. 1°There are still 
no data available to predict factors that will influence lack of tolerability or an 
inadequate response to traditional DMARD treatment. 11 
In the past decade, biologic DMARDs, such as the tumor necrosis factor 
(TNF) antagonists (eg, etanercept,  infliximab, and adalimumab), have become 
firmly established as effective treatments for RA patients with an inadequate 
response to traditional DMARDs. 12-14 The anti-interleukin-1 receptor antagonist 
anakinra is also an alternative treatment option for these patients. 15 However, 
as with traditional DMARDs, some patients (20%-40%) who are treated with 
TNF antagonists do not respond to t reatment 16-18 or may respond initially to 
treatment,  but are unable to sustain the response over time. 19 
The definition of an inadequate response to RA treatment continues to 
evolve, and attempts to clarify the definition have generally been in the context 
of clinical trial data. 2° 
In clinical trials, the identification of an adequate responder  is most com- 
monly based on stringent measures, such as ACR response rates. 21 The ACR 
response rates measure the signs and symptoms of RA based on a number 
of assessments,  including the number of swollen and tender joints, physician 
and patient global assessments of disease activity, and the patient's assess- 
ment of pain. 3 Measurements of ACR response also include laboratory assess- 
ments of acute-phase reactants and physical function, the latter of which is 
evaluated using the Health Assessment Questionnaire (HAQ). 3 The overall 
response rate represents a discontinuous measure of t reatment response and 
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is scored as either ACR 20, 50, or 70, reflecting a 20%, 50%, or 70% improvement, 
respectively. 3 
A second method of assessing clinical improvements uses the Disease 
Activity Score 28 (DAS28). 22 The DAS28 is a continuous measure of disease 
activity that combines information based on how many of 28 joints are swollen 
and tender. Patients' general health and the acute phase response (the eryth- 
rocyte sedimentation rate or C-reactive protein [CRP] concentration) are also 
factored. 22 The DAS28 is scored on a scale ranging from 0 to 9.4, and the abso- 
lute level of disease activity can be selected as a clinically meaningful goal for 
therapeutic intervention. 23A DAS28 >5.1 indicates high-disease activity, >3.2 to 
_<5.1 is classified as moderate-disease activity, <3.2 is defined as the threshold 
for a low-disease activity state, and ~2.6 as the threshold for remission. 23 
Using the described measurements of disease activity, the ACR guidelines 
state that an inadequate response is defined as repetitive flares of RA, ongoing 
disease activity after 3 months of maximal treatment, or progressive joint dam- 
age. 3 In routine clinical practice, it is generally up to the practitioner to decide 
if the patient is experiencing an inadequate response to a course of treatment. 
Patients hould be periodically assessed for levels of disease activity, as conven- 
tionally measured by tender joint counts, swollen joint counts, and the DAS28. 
Validated responses to patient-oriented measures, such as the HAQ Disability 
Index (HAQ-DI) and the Medical Outcomes Survey Short Form-36 (SF-36), are 
also valuable assessment tools and must be considered to determine patient 
response to treatment.  24The HAQ-DI is a self-assessment questionnaire, which 
measures physical impairment and is scored from 0 to 3 (0 = no difficulty and 
3 = unable to perform); a change of >0.22 units is considered to be clinically 
meaningful. 25 Health-related quality of life can be assessed using the self- 
reported SF-36, which is scored from 0 to 100 (a score of 100 indicates perfect 
quality of life)26; a 5- to 10-point change is considered to be a clinically meaning- 
ful improvement. 27 
For a rheumatologist in the day-to-day clinic setting, the management of patients 
experiencing an inadequate response to treatment can be problematic. If a patient 
has an inadequate response to a TNF antagonist, he rheumatologist may switch 
the patient o a different TNF-antagonist agent. Currently available data indicate 
that switching between TNF antagonists to overcome inadequate fficacy or poor 
tolerability may be beneficial. 28 However, patients who fail to respond to their first 
TNF antagonist may show an adequate response to a second TNF antagonist. 28-32 
In addition, in patients who had previously discontinued TNF-antagonist treat- 
ment, the reasons for discontinuing a second TNF antagonist may be related to the 
reasons for discontinuation of the first TNF antagonist. 28Alternatively, instead of 
switching between TNF antagonists, the rheumatologist may choose to increase 
the dose or shorten the administration i terval to improve a patient's response; 
however, there is still no concrete evidence as to whether these are effective 
measures. 33Furthermore, todate, no large controlled clinical trials have effectively 
assessed the benefits of switching between TNF antagonists. 
381 
CURRENT THERAPEUTIC RESEARCH 
Two alternative biologic DMARDs are currently available--rituximab nd 
abatacept. Rituximab is a chimeric anti-CD20 monoclonal antibody that selec- 
tively depletes CD20+ B cells and is indicated for use in combination with 
methotrexate. 34 Abatacept is a selective T-cell costimulation modulator that 
may be used as a monotherapy or in combination with a nonbiologic DMARD. 35 
Rituximab and abatacept are both approved in the United States for the treat- 
ment of patients with an inadequate response to TNF-antagonist treatment. 34,35 
Abatacept is also approved for use in patients who have an inadequate r sponse 
to traditional DMARDs, such as methotrexate. 
Abatacept is a fully soluble human fusion protein that consists of the extra- 
cellular domain of human cytotoxic T-lymphocyte-associated antigen (CTLA)-4 
linked to the Fc (hinge, CH2, and CH3 domains) portion of human immunoglob- 
ulin G1, which has been modified to avoid complement fixation. The mecha- 
nism of action of abatacept differs from that of methotrexate, TNF antagonists, 
and rituximab in that it selectively modulates the activation of T cells. 35-37 To 
become fully activated, T cells require 2 signals. Initially, antigens are proc- 
essed and presented to the T cell by antigen-presenting cells (APCs). 37 After 
antigen recognition, a secondary costimulatory signal is needed to promote full 
T-cell activation. 38 One of the most well characterized costimulatory pathways 
is the engagement of CD80/CD86 on APCs with CD28 on T cells. 37,39 Employing 
the high-binding avidity of CTLA-4 for CD80/CD86 on APCs, abatacept selec- 
tively modulates the CD80/CD86:CD28 costimulatory signal required for full 
T-cell activation (Figure). By targeting the activation of T cells, an upstream 
event in the immune cascade that underlies RA, abatacept has the potential to 
impact multiple downstream aspects of RA immunopathogenesis, uch as the 
production of cytokines, autoantibodies, and inflammatory proteins. 4° 
The purpose of this review was to provide an overview of the clinical trial 
data of abatacept, with a focus on Phase III trial data, in patients with an inad- 
equate response to methotrexate and/or TNF antagonists and to discuss the 
current and future impact of abatacept on the RA treatment armamentarium. 
METHODS 
A search was performed using the MEDLINE, EMBASE, and BIOSIS databases 
(search dates: January 1, 2000-September 19, 2007) for literature using the 
terms abatacept or CTLA-4 or Orencia with rheumatoid arthritis. Full text articles 
in English were selected for relevance, and only articles presenting primary 
clinical trial data from randomized, placebo-controlled clinical trials of abata- 
cept were selected. 
ABATACEPT CLINICAL TRIAL DATA 
The literature search initially yielded 848 papers. Of these, 15 papers were 
excluded, as they were not written in English (no primary abatacept randomized, 
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Figure. Mechanism of action of abatacept. APC = antigen-presenting cell; TNF = tumor 
necrosis factor; IL = interleukin. 
placebo-controlled clinical trials were among these excluded papers). Of the 
remaining 833 papers, 4 were excluded because they were case studies and 247 
because they were reviews, leaving 582 primary papers. A total of 549 papers 
were excluded because they did not describe randomized, placebo-controlled, 
clinical trial data or did not present data in patients with RA. Of the remaining 
33 papers, all of which presented randomized, placebo-controlled clinical trial 
data in patients with RA, 21 were excluded because they presented clinical 
data from RA therapies other than abatacept. Therefore, a total of 12 articles 
fulfilled the inclusion criteria and were included in this article. This review 
focused mainly on the Phase III trials, as these trials had the largest population 
of study patients and the longest study duration. 
Abatacept was the first biologic RA treatment studied in patients with an 
inadequate r sponse to methotrexate and/or TNF antagonists. 41,42 The efficacy 
and tolerability of abatacept in these patient populations have been assessed 
in several randomized, double-blind, placebo-controlled studies in patients 
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aged _>18 years with active RA that was diagnosed according to the ACR and/or 
American Rheumatism Association (ARA) criteria. 41-47 A summary of the trials 
outlined in this review is given in Table I. 41'44'46 
Use of Abatacept in Rheumatoid Arthritis Patients with an 
Inadequate Response to Methotrexate 
Clinical Efficacy 
The Phase III Abatacept in Inadequate responders to Methotrexate (AIM) 
trial was a 1-year, multicenter, andomized, double-blind, placebo-controlled 
study, which examined the efficacy and tolerability of abatacept in patients 
with moderate-to-severe RA and an inadequate response to methotrexate. 44 
Patients were defined as having an inadequate response if they had persis- 
tent RA, which was defined as: >10 swollen joints, >12 tender joints, and CRP 
protein levels of >10.0 mg/L, despite methotrexate reatment (>15 mg/wk for 
>3 months). The primary end points of the study were a 20% improvement in
ACR response criteria (ACR 20) at 6 months, clinically meaningful improve- 
ments (_>0.3 units) 25 in physical function as measured by the HAQ, and change 
from baseline in joint erosion, as measured by the Genant-modified Sharp scale 
score at 1 year. 48,49 Erosions were scored on an 8-point scale (0-3.5, where 
0 = normal and 3 and upwards = severe) at: 10 locations in the hand, 4 in the 
wrist, 5° and 6 in the foot. 48 The joint-space narrowing is scored on a 9-point 
scale (0-4, where 0 = normal and 4 = ankylosed or dislocated) at: 10 locations 
in the hand, 3 in the wrist, 5° and 6 in the foot. 48 The total score is calculated by 
the sum of the erosion plus joint-space narrowing score. 
Physicians who performed the efficacy and tolerability assessments were 
blinded to treatment group assignment. An intent-to-treat pproach was used 
for data analysis, including all patients who received >1 dose of study medica- 
tion. Using a centralized randomization system, a total of 433 patients were 
randomized to receive abatacept (10 mg/kg as a standardized dose via IV infu- 
sion) plus methotrexate (15 mg/wk, or 10 mg/wk if the patient had a history of 
toxicity) and 219 to receive placebo plus methotrexate. Abatacept was adminis- 
tered on days 1, 15, and 29, and then every 28 days up to and including day 337. 
Baseline demographic and clinical characteristics were well matched across 
treatment groups. A total of 89% of the abatacept group and 74% of the placebo 
group completed 1 year of treatment. A higher proportion of the placebo group 
discontinued the study compared with the abatacept group (26% vs 11%). Lack 
of efficacy was the most common reason for discontinuation i the placebo 
group compared with the abatacept group (18% vs 3%), and AEs were the most 
common reason for discontinuation i  the abatacept group compared with the 
placebo group (4% vs 2%, respectively). 
Investigators eported that abatacept treatment was associated with statis- 
tically significant improvements in the signs and symptoms of RA compared 
with placebo, as assessed by ACR responses and the DAS28, in this active- 
disease patient population. 44Following 6 months of treatment, improvements 
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in ACR 20, 50, and 70 response rates were all statistically significant in favor of 
abatacept versus placebo (ACR 20, 68% vs 40%; ACR 50, 40% vs 17%; ACR 70, 
20% vs 7%; all, P < 0.001). The improvements in ACR responses were sustained 
over time, with statistically significant differences maintained in the abatacept 
group compared with the placebo group at 1 year (ACR 20, 73% vs 40%; ACR 
50, 48% vs 18%; ACR 70, 29% vs 6%; all, P < 0.001). A DAS28 score <2.6 has been 
shown to be indicative of clinical remission according to ARA criteria. 51 In the 
AIM trial, 6-month data revealed a statistically significantly higher percentage 
of patients in the abatacept group having a DAS28 score <2.6 compared with 
placebo (14.8% vs 2.8%; P < 0.001). 44 Similar to the ACR response rates, the pro- 
portion of the abatacept group experiencing statistically significant improve- 
ments in DAS28 scores increased from 6 to 12 months compared with patients 
in the placebo group, (6 months, 14.8% vs 2.8%; 12 months, 23.8% vs 1.9% [both, 
P < 0.001]). 
In the AIM trial, at 12 months, the abatacept group had a statistically signifi- 
cant inhibition of structural damage progression, with a decrease of -50% from 
baseline in Genant-modified Sharp scores compared with placebo. The mean 
(median) change from baseline in erosion score was 0.63 (0.0) for abatacept 
versus 1.14 (0.27) for placebo (P = 0.029 for median change). The mean (median) 
change in the joint-space narrowing score was 0.58 (0.0) for abatacept versus 
1.18 (0.0) for placebo (P = 0.009 for median change). The mean (median) change 
in total score was 1.21 (0.0) for abatacept versus 2.32 (0.53) for placebo (P = 0.012 
for median change). 44 
Use of Abatacept in Rheumatoid Arthritis Patients with an 
Inadequate Response to Tumor Necrosis Factor Antagonists 
Clinical Efficacy 
An important patient population with limited treatment options is that of 
patients with an inadequate response to TNF antagonists. These patients typi- 
cally have progressed substantially through the RA treatment paradigm and 
might be receiving concurrent DMARD treatment. 35,41 
The Phase III Abatacept Trial in Treatment of Anti-TNF INadequate responders 
(ATTAIN) was a 6-month, randomized, ouble-blind, placebo-controlled study. 41 
It was the first trial to evaluate the efficacy and tolerability of a biologic agent 
for the treatment of patients with RA with an inadequate response to TNF 
antagonists. 
As in the AIM study, patients were randomized to receive either abatacept 
(10 mg/kg via IV infusion) or placebo in a 2:1 ratio using a centralized randomi- 
zation system. 41 Abatacept was administered on days 1, 15, and 29, and every 
28 days thereafter, up to and including day 141. All patients had to have been 
taking a stable background ose of an oral DMARD or anakinra for _>28 days 
and were allowed to continue to receive their current background DMARD 
medication throughout the study. Stratification according to TNF antagonist 
use was applied as follows: those receiving TNF-antagonist treatment at the 
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time of screening (current users) versus those who had previously failed TNF- 
antagonist treatment (former users). Current users of TNF antagonists had 
their TNF-antagonist treatment withdrawn before randomization. During the 
washout period, the number of tender and swollen joints and CRP concentra- 
tions were assessed to determine whether there was any disease flare in this 
patient population prior to randomization. No statistically significant changes 
were observed in either measure, indicating that no flare occurred and that 
these patients actually were experiencing an inadequate response to their TNF- 
antagonist treatment and had persistent RA. An intent-to-treat population that 
included all randomized patients who received _>1 dose of study drug was used 
for efficacy analyses. All study personnel were blinded to treatment group. 
A total of 258 patients were randomized to abatacept and 133 to placebo (all 
patients continued to receive >1 background DMARD), with 223 (86.4%) and 
99 patients (74.4%), respectively, completing the study. The primary reason for 
discontinuation i  both treatment groups was lack of efficacy (5.4% and 20.3% 
for the abatacept and placebo groups, respectively). Baseline demographic 
and clinical characteristics did not differ significantly across treatment groups. 
Patients in the ATTAIN trial had active disease at baseline, with long-standing 
RA as evidenced by an average disease duration of -12 years (a slightly longer 
disease duration than typical trial populations of patients with an inadequate 
response to methotrexate, such as in the AIM trial44). This was reflected in high 
mean counts of tender and swollen joints (tender joints, 31 and 33, for abata- 
cept and placebo, respectively; swollen joints, 22 for both groups). In addition, 
patients had impaired physical function, as seen in low HAQ-DI scores (1.8 for 
both groups), high DAS28 scores (6.5 for both groups), and elevated CRP con- 
centrations (4.6 mg/dL and 4.0 mg/dL for abatacept and placebo, respectively), 
which are all consistent with active disease. 
The ATTAIN trial found that abatacept treatment was associated with statisti- 
cally significant improvements in the signs and symptoms of RA over 6 months 
compared with placebo-treated patients, as assessed by ACR responses and 
DAS28. 41 The improvements in the ACR response rates for the ATTAIN trial 
were statistically significant for abatacept versus placebo at 6 months: ACR 20, 
50.4% versus 19.5% (P < 0.001); ACR 50, 20.3% versus 3.8% (P < 0.001); and 
ACR 70, 10.2% versus 1.5% (P = 0.003). These statistically significant improve- 
ments were evident in both current and former users of TNF-antagonist treat- 
ment (both, P < 0.001), which suggests that the time between discontinuation 
of TNF-antagonist treatment and the initiation of abatacept treatment did not 
impact he level of benefit achieved. 
In addition to the improvements in ACR scores, a statistically significantly 
higher percentage of patients in the abatacept group achieved a DAS28 score 
indicative of clinical remission (ie, DAS28 <2.6) after 6 months of treatment 
compared with the placebo group (10.0% vs 0.8%; P < 0.001). 41 
A summary of the clinical efficacy after abatacept treatment in patients 
with an inadequate response to methotrexate and in those not responding 
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adequately to TNF antagonists, as found in the AIM 44 and ATTAIN 41 trials, 
respectively, is shown in Table II. 
Improvements in Health-Related Quality of Life with Abatacept 
Abatacept treatment has been found to be associated with cl inical ly mean- 
ingful improvements in all 8 subscales of the SF-36, including the physical and 
the mental component summary scores (PCS and MCS, respectively) in inad- 
equate responders to both methotrexate and TNF antagonists in the AIM and 
ATTAIN trials, respectively. 41,44,52,53 These clinically meaningful improvements 
were also statistically significant in favor of abatacept compared with placebo 
at the respective study end points. In addition, both statistically and clinically 
significant improvements in physical function were seen with abatacept treat- 
ment in both patient populations. 41,44 
After 1 year of treatment in the AIM trial, abatacept was associated with signifi- 
cantly improved patients' physical function, as measured by the HAQ-DI. 44 Clinically 
meaningful improvements in physical function (denoted by an improvement of
>0.3 units from baseline 24) were achieved in 64% of the abatacept group com- 
pared with 39% of the placebo group. 44 Improvements in 5 of the 8 subscales of 
the SF-36 were seen as early as day 29 in the abatacept group. 52 At 6 months, 
the abatacept group had clinically significant improvements (as defined by a 
reduction of 3 units on the SF-36 scale), which were also statistically significant 
compared with the placebo group in all 8 subscales of the SF-36, including 
the PCS (P < 0.001) and MCS (P = 0.009). These improvements were sustained 
over 1 year of treatment and were statistically significant for the abatacept 
group (PCS, P < 0.001; MCS, P = 0.038). 44 At year 1, there were also statistically 
significant improvements for the abatacept group compared with the placebo 
group with regard to change from baseline in activity limitation (-8.4 vs -4.5; 
P< 0.001), fatigue severity (-25.9 vs -17.3; P = 0.003), and sleep problems (-10.4 vs 
-7.2; P = 0.019). 54 At year 1, a statistically significantly higher proportion of the 
abatacept group compared with the placebo group had improvements in daily 
activity (58.7% vs 44.5%; P = 0.001), fatigue (69.1% vs 51.1%; P< 0.001), and sleep 
(58.0% vs 46.7%; P = 0.005). These improvements were defined as being clini- 
cally meaningful, as they exceeded the minimal clinically important differences 
(MCIDs) for activity limitation, fatigue, and sleep (4, 10, and 6, respectively). 
Improvements in fatigue for the abatacept group were observed as early as day 29 
in the AIM trial. 52 
In the ATTAIN trial, 47% of the patients in the abatacept group achieved 
clinically meaningful improvements in physical function compared with 23% 
of patients in the placebo group (P < 0.001). 41 Patients in the ATTAIN trial were 
functioning between 1 and 2 SDs below the norm in terms of health-related 
quality of life (HRQoL). 53 At 6 months, the abatacept group had statistically 
significantly greater improvements compared with the placebo group in all 
8 subscales of the SF-36, including the PCS and MCS (P < 0.001 and P < 0.01, 
respectively). 41 These improvements in the abatacept group were also clini- 
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cally meaningful. At 6 months, greater and statistically significant reductions 
in activity limitation were reported for the abatacept group compared with the 
placebo group (-7.4 vs -1.3; P < 0.001). Significant reductions in fatigue severity 
(-22.3 vs -5.3; P < 0.001) and sleep problems (-9.8 vs -2.1; P < 0.001) were also 
noted. 54 At 6 months, a higher proportion of the abatacept group compared 
with the placebo group had clinically meaningful improvements, which were 
statistically significant in favor of abatacept in activity limitation (53.1% vs 
31.1%; P < 0.001), fatigue (58.5% vs 37.1%; P < 0.001), and sleep (58.9% vs 37.9%; 
P < 0.001), as defined by improvements exceeding the MCIDs of 4, 10, and 6, 
respectively. 54 Across both the AIM and ATTAIN trials, rapid improvements in 
HRQoL outcomes, such as fatigue, were observed as early as 4 and 2 weeks, 
respectively, which support he suggestion that clinically meaningful changes 
are provided to patients. 52,53 
Improvements in HRQoL seen with abatacept have a strong correlation with 
clinical responses: the greatest improvements in HRQoL (SF-36) were observed 
in patients achieving a higher ACR response, while the smallest improve- 
ments in HRQoL were observed in patients who failed to achieve an ACR 20 
response. 52This illustrates the positive relationship between the level of ACR 
improvement and improvements in HRQoL measurements and suggests that 
the clinical efficacy seen with abatacept may translate into tangible benefits 
for the patient. 
Safety Profile and Tolerability of Abatacept 
The tolerability of abatacept has been studied in 5 trials, including the AIM 
and ATTAIN trials and an additional Phase III trial, the Abatacept Study of 
Safety in Use with other RA therapies (ASSURE) trial. This trial was designed 
to encompass a wide range of RA patients receiving a variety of nonbiologic 
and biologic background RA therapies, a patient population that is regularly 
encountered in routine clinical practice. 46 
A tolerability analysis 35 performed by the drug manufacturer included data 
from the AIM, ATTAIN, and ASSURE trials, along with 2 other 1-year, Phase IIb, 
randomized, placebo-controlled clinical trials: abatacept in combination with 
etanercept 47 in etanercept inadequate responders and abatacept plus metho- 
trexate in patients who had an inadequate response to methotrexate. 43 These 
were placebo-controlled trials of abatacept, which had a double-blind period of 
6 months (258 and 133 patients in the abatacept and placebo groups, respec- 
tively) or 12 months (1697 and 856 in the abatacept and placebo groups, respec- 
tively), with a total of 1955 patients in the abatacept group and 989 in the placebo 
group. Data from this analysis indicate that abatacept was generally well toler- 
ated in patients with an inadequate r sponse to methotrexate or to TNF antago- 
nists when used in combination with nonbiologic background DMARDs. 
The most commonly reported AEs, which occurred in >3% of all patients and 
>1% more frequently in abatacept-treated patients were: headache (18%), naso- 
pharyngitis (12%), dizziness (9%), and cough (8%). 35 Infections were reported in 
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54% of the abatacept group and 48% of the placebo group, and the overall fre- 
quencies of malignancies were similar in both groups (1.3% and 1.1%, respec- 
tively). In the double-blind periods (1955 patients in the abatacept group), a 
total of 4 cases of lung cancer (0.2%) were reported in the abatacept group 
compared with 0 cases in the placebo group. In the cumulative period (place- 
bo-controlled and uncontrolled, open-label trials), a total of 8 cases of lung 
cancer (0.21 cases per 100 patient-years) and 4 of lymphomas (0.10 cases per 
100 patient-years) were observed in 2688 patients (a total of 3827 patient-years). 
Although the role of abatacept in the development of malignancies is unknown, 
patients with active RA are at a greater isk for the development of lymphoma 
(-3.5-fold higher than expected in an age- and gender-matched general popula- 
tion based on the Surveillance, Epidemiology and End Results Database 
[National Cancer Institute, Bethesda, Maryland]). 
The ASSURE trial was a 1-year, randomized, ouble-blind, placebo-controlled 
study, designed to investigate he safety of abatacept in patients receiving back- 
ground biologic/nonbiologic DMARDs. A total of 1231 patients with active RA, 
despite receiving biologic/nonbiologic DMARDs (>1 medication for >3 months) 
were included and received abatacept or placebo. Abatacept was administered 
as an IV infusion, at a dose of 10 mg/kg, according to weight range, on days 1, 
15, 29 and every 4 weeks thereafter. Patients continued to receive background 
biologic/nonbiologic therapy throughout the trial. 
Investigators eported that when comparing the abatacept-treated patients 
in the subgroups receiving background biologic and nonbiologic treatment, 
there was an increase in discontinuations, AEs, and serious AEs in the biologic- 
background-treatment subgroup. 46Serious infections in the abatacept-treated 
patients in the biologic versus nonbiologic subgroup were 5.8% vs 2.6%, respec- 
tively. These findings are consistent with previous trials that attempted tocombine 
2 biologic agents. 35,47 In a trial that investigated the efficacy and safety of abatacept 
in combination with etanercept, 16.5% of patients receiving these 2 biologic thera- 
pies experienced serious AEs, compared with 2.8% patients in the etanercept lus 
placebo group. 47 Serious infections were experienced by 3.5% and 0% patients, in 
the etanercept lus abatacept and etanercept lus placebo groups, respectively. 
Based on the evidence from that trial and the results of the ASSURE trial, 46 abata- 
cept used concurrently with another biologic is not recommended. 35 
Pulmonary AEs, such as the exacerbation of chronic obstructive pulmonary 
disease (COPD), have been noted in clinical trials with biologic DMARDs, such 
as TNF antagonists. 55,56 In the ASSURE trial, 37 patients with COPD were treated 
with abatacept and 17 patients with COPD were administered placebo. 46 A total 
of 43% of abatacept-treated patients experienced a respiratory disorder AE, 
such as exacerbation of COPD, compared with 24% placebo-treated patients. 
Therefore, patients with RA and COPD should be monitored closely when 
receiving abatacept. 35 
It has been recommended that RA patients treated with TNF antagonists 
should be screened for latent uberculosis. 57 Prior to randomization i  the AIM 
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trial, all patients were evaluated for latent tuberculosis infection. 44 Patients 
who were positive for the purified protein derivative test were excluded from 
the trial. Since abatacept has not been studied in patients with a positive tuber- 
culosis screening examination, the tolerability of abatacept in individuals with 
latent tuberculosis infection is unknown. Additional ong-term data are needed 
to ascertain if there is a link between abatacept treatment and an increase in 
the relative risk of tuberculosis. 
The safety and tolerabil ity profile of abatacept has been found to be con- 
sistent throughout  t reatment over 1 year. 35 However, further observat ions in 
routine clinical practice are required to fully document  he long-term safety 
and tolerability data. 
Reports of acute infusion-related events (AEs occurr ing <1 hour after 
the start  of the infusion), which were assessed in Phase III trials only, were 
reported in 9% of abatacept-treated patients compared with 6% of placebo- 
treated patients. However, <1% of the abatacept group discontinued ue to an 
acute infusion-related event. 35 
DISCUSSION 
Rheumatologists and patients current ly have a var iety of options available for 
the treatment of RA. Patients are generally prescr ibed traditional DMARDs as 
first-line treatment.  3 However, discontinuation rates are generally high (-40% to 
50%) and are primarily associated with either a lack of efficacy or safety issues. 
Biologic DMARD therapies, such as TNF antagonists, have provided clinical 
benefits to these patients and, therefore, offer valuable alternative treatment 
options. However, it has been reported that 20% to 40% of patients have an 
inadequate response to TNF antagonists, and switching between these agents, 
increasing the dose, or decreasing the administration i terval may not be effec- 
tive in all patients. 33 There are also no clear guidelines available on the effective 
management of inadequate responders to TNF antagonists. 
Before the approval of r ituximab and abatacept, patients deemed to have an 
inadequate response to TNF-antagonist t reatment had limited future treatment 
options. Abatacept is indicated either as a monotherapy or in combination 
with other nonbiologic DMARDs in patients with an inadequate response to 
methotrexate, as well as TNF antagonists. Abatacept provides a valuable treat- 
ment option for use in adult patients with moderate-to-severe RA who have not 
benefited from previous methotrexate or TNF-antagonist treatment. 
The clinical profile of abatacept, as assessed by multiple measures of clinical 
efficacy in Phase III clinical trials, indicates that this recent addition to the RA 
treatment paradigm provides ignificant clinical benefit and a consistent safety 
profile in patients who have exper ienced an inadequate response to methotrex- 
ate and for those who have not responded to TNF antagonists. Notable bene- 
fits with abatacept in both patient populations include clinically meaningful 
improvements in HRQoL (eg, fatigue) within the first month of treatment, as well 
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as in the durability of the clinical response and safety profile seen with treat- 
ment. By improving HRQoL, abatacept might also provide benefits for patients 
with RA with previous inadequate r sponses to standard treatment. Long-term 
studies are needed to continually assess the efficacy, HRQoL, and tolerability of 
abatacept and to further support he findings outlined in this review. 
In this analysis, there were no stringent predefined inclusion and exclusion 
criteria used to select the studies. Only randomized, double-blind, placebo- 
controlled primary abatacept clinical data were included, and papers were 
only included if they were written in English. These inclusion criteria could 
potentially have introduced bias into the search results, as only published full 
manuscripts were selected, thereby excluding abstracts. In addition, the qual- 
ity and validity of the included publications were not assessed. 
The findings from long-term extension periods of the AIM 58 and ATTAIN 59 
trials will be published in the near future (both presenting 2-year data), adding 
to the long-term efficacy and safety experience of abatacept. A Phase IIIb, ran- 
domized, double-blind, placebo-controlled, parallel-assignment study of abata- 
cept or infliximab in combination with methotrexate in controlling disease 
activity in patients with RA having an inadequate response to methotrexate 
has now been completed. 6° Even though this study was not designed to specifi- 
cally compare the efficacy of abatacept with infliximab, this is the first trial to 
incorporate 2 biologic treatment arms in a single study. 
Other recently completed, but as yet unpublished, abatacept trials include 
an evaluation of the tolerability of abatacept in children and adolescents with 
active polyarticular juvenile RA. 61 Trials assessing abatacept treatment in early 
RA are also being conducted. 62 Other ongoing trials include the evaluation of 
the tolerability and efficacy of abatacept in populations other than in the United 
States that have an inadequate response to methotrexate, such as Korean and 
Japanese patients with RA. 63-65 The results of these trials and use in routine 
clinical practice will add to the current knowledge regarding the efficacy and 
safety data already available on abatacept. 
CONCLUSION 
The efficacy and tolerability data from Phase III clinical trials suggest that abata- 
cept is an effective and generally well tolerated treatment option for RA patients 
with an inadequate r sponse to methotrexate and/or TNF antagonists. 
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